An update on computational oral absorption simulation

Introduction: Within the last decades, computational models have developed rapidly and some of these models have proven useful in understanding how physiological, physicochemical and formulation factors affect oral drug absorption. Nowadays, complex computer-based absorption models are being used as standard tools in both academia and the pharmaceutical industry at several stages of the drug development process. Areas covered: Areas covered include the progress of computational tools for predicting drug absorption. The various qualitative and quantitative approaches that have been proposed are summarized, with special emphasis on a key tool for predicting oral drug absorption, physiologically based pharmacokinetic modeling (PBPK). The theories of the different models are described and recent applications within drug research and development are summarized and evaluated. Additionally, the current state of computational absorption models is discussed, including areas for potential improvements. Expert opinion: The field of pharmacokinetics modeling has undergone a major transformation over the last 10 – 20 years and there will most likely be even more exciting developments ahead. With the availability of generic physiologically based absorption models, more and more case examples using PBPK models have been published that demonstrate either improved ability to predict oral drug absorption or have allowed a more mechanistic interpretation of experimentally observed data.

[1]  M E Andersen,et al.  Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.

[2]  M. DeVito,et al.  Physiologically based pharmacokinetic modeling of deltamethrin: development of a rat and human diffusion-limited model. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Jan Meulenbelt,et al.  A Human Physiologically-Based Model for Glycyrrhzic Acid, A Compound Subject to Presystemic Metabolism and Enterohepatic Cycling , 2000, Pharmaceutical Research.

[4]  V. Lukacova,et al.  Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food Effects , 2009, The AAPS Journal.

[5]  Stefan S De Buck,et al.  Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation , 2007, Expert opinion on drug metabolism & toxicology.

[6]  Jürgen B. Bulitta,et al.  Physiologically Based Pharmacokinetics of Zearalenone , 2009, Journal of toxicology and environmental health. Part A.

[7]  A. Galetin,et al.  Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. , 2009, Journal of pharmaceutical sciences.

[8]  K. Higaki,et al.  Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.

[9]  J. Wagner,et al.  KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG. , 1964, Journal of pharmaceutical sciences.

[10]  Isadore Kanfer,et al.  Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  Michael B. Bolger,et al.  In Silico Modeling of Non-Linear Drug Absorption for the P-gp Substrate Talinolol and of Consequences for the Resulting Pharmacodynamic Effect , 2006, Pharmaceutical Research.

[12]  Hiroshi Yamazaki,et al.  Human Blood Concentrations of Cotinine, a Biomonitoring Marker for Tobacco Smoke, Extrapolated from Nicotine Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling , 2010, International journal of environmental research and public health.

[13]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[14]  David G Levitt,et al.  PKQuest: measurement of intestinal absorption and first pass metabolism – application to human ethanol pharmacokinetics , 2002, BMC clinical pharmacology.

[15]  T. Kararli Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[16]  Raimar Löbenberg,et al.  Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  Tycho Heimbach,et al.  Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data , 2009, The AAPS Journal.

[18]  D T Mauger,et al.  In vitro-in vivo relationships for oral extended-release drug products. , 1997, Journal of biopharmaceutical statistics.

[19]  Michael B. Bolger,et al.  Prediction of Modified Release Pharmacokinetics and Pharmacodynamics from In Vitro, Immediate Release, and Intravenous Data , 2009, The AAPS Journal.

[20]  A Rostami-Hodjegan,et al.  Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.

[21]  R. J. Lutz,et al.  A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  J. F. Gross,et al.  Physiologically based pharmacokinetic models for anticancer drugs , 2004, Cancer Chemotherapy and Pharmacology.

[23]  J. Wagner,et al.  Absorption of Flurbiprofen in the Fed and Fasted States , 1992, Pharmaceutical Research.

[24]  C. Goodman United States Pharmacopeial Convention , 1988 .

[25]  Stefan Willmann,et al.  Development and Validation of a Physiology-based Model for the Prediction of Oral Absorption in Monkeys , 2007, Pharmaceutical Research.

[26]  M. Pocard,et al.  Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. , 2010, Molecular pharmaceutics.

[27]  Guanghua Gao,et al.  Physiologically Based Pharmacokinetics of Matrine in the Rat after Oral Administration of Pure Chemical and ACAPHA , 2009, Drug Metabolism and Disposition.

[28]  Hiroshi Yamazaki,et al.  Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. , 2010, Regulatory toxicology and pharmacology : RTP.

[29]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[30]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[31]  K. Pang,et al.  A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[32]  M. Jamei,et al.  A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model , 2007 .

[33]  J. Parojčić,et al.  In Vitro–In Vivo Correlation for Gliclazide Immediate-Release Tablets Based on Mechanistic Absorption Simulation , 2011, AAPS PharmSciTech.

[34]  Jennifer B Dressman,et al.  Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[36]  Thierry Lavé,et al.  An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. , 2005, Journal of pharmaceutical sciences.

[37]  Jin Y. Jin,et al.  Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism. , 2010, Journal of pharmaceutical sciences.

[38]  J. Dressman,et al.  Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.

[39]  Chensheng Lu,et al.  The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment , 2009, Environmental health perspectives.

[40]  H J Clewell,et al.  A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.

[41]  J. Fisher,et al.  Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[42]  H. Lennernäs,et al.  Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. , 2004, Molecular pharmaceutics.

[43]  Filippos Kesisoglou,et al.  Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[45]  M. Andersen,et al.  Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. , 2007, Toxicology.

[46]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[47]  M E Meek,et al.  Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. , 2003, Regulatory toxicology and pharmacology : RTP.

[48]  Sarah Whalley,et al.  Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling , 2010, Clinical pharmacokinetics.

[49]  J. Morais,et al.  The new European Medicines Agency guideline on the investigation of bioequivalence. , 2010, Basic & clinical pharmacology & toxicology.

[50]  Alan Jones,et al.  To whom correspondence should be addressed , 2014 .

[51]  Jennifer B Dressman,et al.  Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[52]  Filippos Kesisoglou,et al.  Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[53]  Stefan Willmann,et al.  Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. , 2009, The Journal of pharmacy and pharmacology.

[54]  A. McLachlan,et al.  Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans , 2002, Antimicrobial Agents and Chemotherapy.

[55]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[56]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[57]  Nigel J Walker,et al.  Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses. , 2002, Regulatory toxicology and pharmacology : RTP.

[58]  Michael B. Bolger,et al.  Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine , 2009, The AAPS Journal.

[59]  Sheila Annie Peters,et al.  Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[60]  L. A. Fenu,et al.  The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.

[61]  Harvey Wong,et al.  Interplay of Dissolution, Solubility, and Nonsink Permeation Determines the Oral Absorption of the Hedgehog Pathway Inhibitor GDC-0449 in Dogs: An Investigation Using Preclinical Studies and Physiologically Based Pharmacokinetic Modeling , 2010, Drug Metabolism and Disposition.

[62]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. , 2008, Expert opinion on drug metabolism & toxicology.

[63]  R. Saito,et al.  Quantitative analysis of the effect of supersaturation on in vivo drug absorption. , 2010, Molecular pharmaceutics.

[64]  Tau Fluvalinate,et al.  The European Agency for the Evaluation of Medicinal Products , 1997 .

[65]  F Kesisoglou,et al.  Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[66]  G. Amidon,et al.  Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.

[67]  J. Dressman,et al.  Towards Quantitative Prediction of Oral Drug Absorption , 2008, Clinical pharmacokinetics.

[68]  I. Gardner,et al.  Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[69]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[70]  H. Métivier A new model for the human alimentary tract: the work of a Committee 2 task group. , 2003, Radiation protection dosimetry.

[71]  Xh Huang,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2010 .

[72]  S. Yamashita,et al.  Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.

[73]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[74]  Patrick Poulin,et al.  Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.

[75]  A. Oomen,et al.  Development of an In Vitro Digestion Model for Estimating the Bioaccessibility of Soil Contaminants , 2003, Archives of environmental contamination and toxicology.

[76]  K. Bischoff,et al.  Models of ARA-C chemotherapy of L1210 leukemia in mice , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[77]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[78]  H. Haggard,et al.  THE ABSORPTION, DISTRIBUTION, AND ELIMINATION OF ETHYL ETHER , 1957 .

[79]  Walter Schmitt,et al.  Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.

[80]  H. Haggard I. THE AMOUNT OF ETHER ABSORBED IN RELATION TO THE CONCENTRATION INHALED AND ITS FATE IN THE BODY , 1924 .

[81]  Ryosei Kawai,et al.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[82]  John G. Wagner,et al.  Fundamentals of Clinical Pharmacokinetics , 1975 .

[83]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[84]  Matthew A. Bazar,et al.  Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats , 2009, Journal of applied toxicology : JAT.

[85]  Sang Wook Hwang,et al.  Assessment of Bisphenol a Exposure in Korean Pregnant Women by Physiologically Based Pharmacokinetic Modeling , 2010, Journal of toxicology and environmental health. Part A.

[86]  A. Brochot,et al.  Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. , 2010, Basic & clinical pharmacology & toxicology.

[87]  Michael Levin Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[88]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[89]  Yasuhiro Tsume,et al.  The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. , 2010, Molecular pharmaceutics.

[90]  Kazutaka Higaki,et al.  Gastrointestinal transit and drug absorption. , 2000, Biological & pharmaceutical bulletin.

[91]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[92]  Y. Liu,et al.  A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs. , 2011, Journal of veterinary pharmacology and therapeutics.

[93]  J. Dressman,et al.  Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. , 2011, Journal of pharmaceutical sciences.

[94]  G. Grass,et al.  Simulation models to predict oral drug absorption from in vitro data , 1997 .

[95]  G L Amidon,et al.  Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[96]  Fan Zhang,et al.  Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration , 2011, Drug Metabolism and Disposition.

[97]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[98]  A. Urtti,et al.  Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[99]  Andrea N. Edginton,et al.  Predicting Plasma Concentrations of Bisphenol A in Children Younger Than 2 Years of Age after Typical Feeding Schedules, using a Physiologically Based Toxicokinetic Model , 2008, Environmental health perspectives.

[100]  Thierry Lavé,et al.  Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. , 2005, Basic & clinical pharmacology & toxicology.

[101]  S. Willmann,et al.  Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.

[102]  Jelena Parojcić,et al.  Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. , 2009, Molecular pharmaceutics.

[103]  M. Andersen,et al.  A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat. , 1998, Toxicology and applied pharmacology.

[104]  Rogelio Tornero-Velez,et al.  Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. , 2010, Toxicology and applied pharmacology.

[105]  P J Sinko,et al.  Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Kenneth B. Bischoff,et al.  Mathematical representations of cancer chemotherapy effects , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[107]  Thierry Lavé,et al.  Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[108]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[109]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[110]  Michael B. Bolger,et al.  Application of Gastrointestinal Simulation for Extensions for Biowaivers of Highly Permeable Compounds , 2008, The AAPS Journal.

[111]  Thierry Lavé,et al.  Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.

[112]  Robert Tardif,et al.  Development of Physiologically Based Toxicokinetic Models for Improving the Human Indoor Exposure Assessment to Water Contaminants: Trichloroethylene and Trihalomethanes , 2006, Journal of toxicology and environmental health. Part A.

[113]  Raimar Löbenberg,et al.  Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug , 2008, Pharmaceutical Research.

[114]  Simon Thomas,et al.  Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. , 2008, Journal of pharmaceutical sciences.

[115]  G. Levy EFFECT OF DOSAGE FORM ON DRUG ABSORPTION A FREQUENT VARIABLE IN CLINICAL PHARMACOLOGY. , 1964, Archives internationales de pharmacodynamie et de therapie.

[116]  J. Dressman,et al.  Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. , 2010, Journal of pharmaceutical sciences.

[117]  Chad Stoner,et al.  Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. , 2006, International journal of pharmaceutics.

[118]  Stefan Willmann,et al.  Physiology-Based Simulations of a Pathological Condition , 2008, Clinical pharmacokinetics.

[119]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[120]  Edda Klipp,et al.  Systems Biology , 1994 .

[121]  J. Dressman,et al.  Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.

[122]  Hugh A. Barton,et al.  Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[123]  Donald E Mager,et al.  Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[124]  Sheila Annie Peters,et al.  Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles , 2008, Clinical pharmacokinetics.

[125]  Umesh V. Banakar,et al.  Pharmaceutical Dissolution Testing , 1991 .

[126]  K. Pang,et al.  Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[127]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[128]  Christos Reppas,et al.  Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration , 2001, Pharmaceutical Research.

[129]  Patrick Poulin,et al.  Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.

[130]  D. Levitt PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol , 2002, BMC clinical pharmacology.

[131]  R. Löbenberg,et al.  Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.

[132]  M. Andersen,et al.  A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. , 1997, Toxicology.

[133]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[134]  Chensheng Lu,et al.  Assessing Children’s Dietary Pesticide Exposure: Direct Measurement of Pesticide Residues in 24-Hr Duplicate Food Samples , 2010, Environmental health perspectives.

[135]  Martin Kuentz,et al.  Drug Absorption Modeling as a Tool to Define the Strategy in Clinical Formulation Development , 2008, The AAPS Journal.

[136]  Yatindra Joshi,et al.  Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. , 2004, Journal of pharmaceutical sciences.

[137]  Rogelio Tornero-Velez,et al.  Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[138]  M. Durisová,et al.  Physiologically motivated time-delay model to account for mechanisms underlying enterohepatic circulation of piroxicam in human beings. , 2009, Basic & clinical pharmacology & toxicology.

[139]  Peter Langguth,et al.  An Investigation into the Importance of “Very Rapid Dissolution” Criteria for Drug Bioequivalence Demonstration using Gastrointestinal Simulation Technology , 2009, The AAPS Journal.

[140]  S. Riegelman,et al.  New method for calculating the intrinsic absorption rate of drugs. , 1968, Journal of pharmaceutical sciences.

[141]  W. Schmitt,et al.  A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats , 2003, Pharmaceutical Research.

[142]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[143]  Stefan Willmann,et al.  Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[144]  Lawrence X. Yu,et al.  Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development , 2011, The AAPS Journal.

[145]  G. Loizou,et al.  A human PBPK model for ethanol describing inhibition of gastric motility , 2004, Journal of Molecular Histology.

[146]  Stefan Willmann,et al.  Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. , 2012, Journal of pharmaceutical sciences.